patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_877256 | REC_0008701 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11.8 | 83 | female | 1 | 20 | 7.5 | 6 | entrectinib 600 mg daily | 15.5 | true | MSI-H | 2026-03-15T05:35:58.996852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175653 | REC_0008702 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 14.7 | 77 | female | 2 | 19 | 4.5 | 5 | entrectinib 600 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:58.997090+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256379 | REC_0008703 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 16.5 | 83 | female | 2 | 10 | 4.7 | 4 | sotorasib 960 mg daily | 14.4 | true | MSI-H | 2026-03-15T05:35:58.997328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378661 | REC_0008704 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 10.7 | 63 | male | 0 | 16 | 6.7 | 5 | pembrolizumab 200 mg q3w | 15.8 | false | MSS | 2026-03-15T05:35:58.997564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365622 | REC_0008705 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 7.2 | 77 | female | 1 | 29 | 4.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.3 | false | MSS | 2026-03-15T05:35:58.997795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890404 | REC_0008706 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 11.6 | 61 | male | 0 | 15 | 2.9 | 3 | alectinib 600 mg BID | 13.9 | false | MSI-H | 2026-03-15T05:35:58.998033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892099 | REC_0008707 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 16 | 82 | female | 2 | 13 | 7.5 | 5 | osimertinib 80 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:35:58.998268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493458 | REC_0008708 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 19 | 67 | female | 1 | 8 | 5.4 | 5 | osimertinib 80 mg daily | 8.7 | false | MSS | 2026-03-15T05:35:58.998498+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155481 | REC_0008709 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 13 | 14.3 | 64 | female | 0 | 14 | 5.2 | 6 | pembrolizumab 200 mg q3w | 18.4 | true | MSS | 2026-03-15T05:35:58.998734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202620 | REC_0008710 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 9.3 | 69 | female | 1 | 21 | 4.7 | 4 | osimertinib 80 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:58.998959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350993 | REC_0008711 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.2 | 64 | male | 1 | 69 | 5.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 20 | false | MSS | 2026-03-15T05:35:58.999238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532889 | REC_0008712 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 6.6 | 74 | male | 2 | 15 | 5.8 | 7 | osimertinib 80 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:58.999474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_854395 | REC_0008713 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 8.8 | 78 | female | 2 | 12 | 6.4 | 5 | pembrolizumab 200 mg q3w | 11.7 | false | MSS | 2026-03-15T05:35:58.999703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567637 | REC_0008714 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 11.4 | 71 | female | 3 | 9 | 6.6 | 2 | osimertinib 80 mg daily | 20.6 | true | MSI-H | 2026-03-15T05:35:58.999939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948405 | REC_0008715 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 15 | 14.9 | 46 | male | 0 | 24 | 4 | 1 | osimertinib 80 mg daily | 18.9 | false | MSS | 2026-03-15T05:35:59.000202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113551 | REC_0008716 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 36 | 13.6 | 70 | female | 2 | 14 | 5.3 | 6 | osimertinib 80 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:59.000437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852622 | REC_0008717 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.5 | 53 | female | 0 | 57 | 7.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 15.8 | false | MSS | 2026-03-15T05:35:59.000669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156164 | REC_0008718 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 12.4 | 66 | female | 1 | 9 | 5.7 | 1 | alectinib 600 mg BID | 9.1 | false | MSI-H | 2026-03-15T05:35:59.000904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769800 | REC_0008719 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 5.1 | 70 | male | 1 | 24 | 8.6 | 1 | pembrolizumab 200 mg q3w | 23.6 | false | MSS | 2026-03-15T05:35:59.001140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924114 | REC_0008720 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 32 | 14.4 | 62 | male | 1 | 18 | 6.2 | 0 | sotorasib 960 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:59.001377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873583 | REC_0008721 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.4 | 52 | male | 0 | 49 | 4.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.6 | true | MSS | 2026-03-15T05:35:59.001610+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662979 | REC_0008722 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 16.8 | 68 | male | 0 | 20 | 2 | 1 | entrectinib 600 mg daily | 17.1 | true | MSI-H | 2026-03-15T05:35:59.001849+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173376 | REC_0008723 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 6.8 | 67 | male | 0 | 12 | 5.7 | 6 | osimertinib 80 mg daily | 5.7 | false | MSS | 2026-03-15T05:35:59.002085+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805402 | REC_0008724 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 12.4 | 72 | female | 2 | 5 | 6.6 | 1 | sotorasib 960 mg daily | 19.1 | false | MSS | 2026-03-15T05:35:59.002367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844259 | REC_0008725 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 4.2 | 62 | female | 1 | 18 | 5.7 | 2 | pembrolizumab 200 mg q3w | 14 | true | MSS | 2026-03-15T05:35:59.002604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657830 | REC_0008726 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 11.9 | 71 | male | 2 | 12 | 3.9 | 7 | osimertinib 80 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:59.003086+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222918 | REC_0008727 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 6.5 | 71 | female | 3 | 17 | 5 | 2 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:59.003336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370181 | REC_0008728 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 14.6 | 55 | male | 1 | 11 | 4.7 | 6 | sotorasib 960 mg daily | 8.4 | false | MSS | 2026-03-15T05:35:59.003586+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449021 | REC_0008729 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 35 | 4.6 | 68 | female | 1 | 39 | 7.6 | 6 | pembrolizumab 200 mg q3w | 12.4 | false | MSS | 2026-03-15T05:35:59.003821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690264 | REC_0008730 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 9 | 86 | female | 2 | 20 | 5.3 | 1 | pembrolizumab 200 mg q3w | 19.8 | false | MSS | 2026-03-15T05:35:59.004053+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237223 | REC_0008731 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 5.6 | 66 | female | 0 | 16 | 5.5 | 4 | osimertinib 80 mg daily | 9.8 | true | MSS | 2026-03-15T05:35:59.004321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951836 | REC_0008732 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 15 | 49 | male | 0 | 3 | 6.3 | 7 | entrectinib 600 mg daily | 10.9 | true | MSS | 2026-03-15T05:35:59.004557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946633 | REC_0008733 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 16.4 | 69 | female | 0 | 12 | 6.6 | 6 | osimertinib 80 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:35:59.004791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878744 | REC_0008734 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 22 | 8.6 | 62 | female | 1 | 19 | 5.8 | 0 | entrectinib 600 mg daily | 40.9 | false | MSS | 2026-03-15T05:35:59.005030+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360124 | REC_0008735 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 10.9 | 70 | male | 2 | 9 | 6.8 | 2 | osimertinib 80 mg daily | 12 | true | MSI-H | 2026-03-15T05:35:59.005269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938065 | REC_0008736 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 3.7 | 63 | male | 1 | 14 | 6 | 2 | entrectinib 600 mg daily | 16.1 | false | MSS | 2026-03-15T05:35:59.005506+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705597 | REC_0008737 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 13.1 | 62 | female | 1 | 15 | 6.6 | 6 | osimertinib 80 mg daily | 15.4 | false | MSI-H | 2026-03-15T05:35:59.005815+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686248 | REC_0008738 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 13.7 | 76 | female | 1 | 11 | 3.6 | 5 | alectinib 600 mg BID | 19.5 | false | MSS | 2026-03-15T05:35:59.006056+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411620 | REC_0008739 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.2 | 68 | female | 0 | 55 | 6.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.7 | false | MSS | 2026-03-15T05:35:59.006287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508536 | REC_0008740 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 17 | 69 | female | 1 | 17 | 6.2 | 1 | osimertinib 80 mg daily | 15.6 | true | MSS | 2026-03-15T05:35:59.006521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255314 | REC_0008741 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 6.3 | 56 | male | 0 | 9 | 7.5 | 6 | sotorasib 960 mg daily | 4.5 | false | MSS | 2026-03-15T05:35:59.006757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114856 | REC_0008742 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.1 | 71 | female | 2 | 53 | 6 | 3 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:59.006986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748918 | REC_0008743 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 34 | 10.5 | 71 | female | 1 | 12 | 5.6 | 2 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:59.007219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731028 | REC_0008744 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 6.8 | 60 | female | 0 | 9 | 4.5 | 4 | osimertinib 80 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:59.007454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262246 | REC_0008745 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 4.5 | 70 | female | 2 | 58 | 5 | 6 | pembrolizumab 200 mg q3w | 7.8 | false | MSS | 2026-03-15T05:35:59.007682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176115 | REC_0008746 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 10.2 | 63 | male | 0 | 16 | 5.5 | 6 | osimertinib 80 mg daily | 5.6 | true | MSS | 2026-03-15T05:35:59.007920+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_259590 | REC_0008747 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 17 | 80 | female | 1 | 25 | 4.1 | 2 | alectinib 600 mg BID | 12.8 | false | MSS | 2026-03-15T05:35:59.008230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_195435 | REC_0008748 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11.4 | 45 | female | 0 | 16 | 4.2 | 6 | entrectinib 600 mg daily | 20.6 | false | MSS | 2026-03-15T05:35:59.008475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381878 | REC_0008749 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.7 | 80 | female | 1 | 21 | 6 | 2 | alectinib 600 mg BID | 8 | false | MSI-H | 2026-03-15T05:35:59.008711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856247 | REC_0008750 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 22 | 8.2 | 64 | female | 0 | 20 | 4 | 0 | osimertinib 80 mg daily | 22.2 | false | MSS | 2026-03-15T05:35:59.008994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413786 | REC_0008751 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 4.9 | 58 | male | 0 | 11 | 7.5 | 1 | alectinib 600 mg BID | 16.7 | false | MSS | 2026-03-15T05:35:59.009232+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677990 | REC_0008752 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 19.9 | 65 | female | 1 | 14 | 4.4 | 4 | sotorasib 960 mg daily | 4.9 | false | MSI-H | 2026-03-15T05:35:59.009467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834594 | REC_0008753 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 32 | 10.8 | 63 | male | 0 | 20 | 6 | 5 | pembrolizumab 200 mg q3w | 8.5 | false | MSS | 2026-03-15T05:35:59.009703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650806 | REC_0008754 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 15.9 | 71 | female | 2 | 24 | 5 | 5 | osimertinib 80 mg daily | 8.4 | true | MSS | 2026-03-15T05:35:59.009936+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734393 | REC_0008755 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 11.1 | 86 | female | 2 | 21 | 6.8 | 8 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.010171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692047 | REC_0008756 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.5 | 69 | male | 1 | 12 | 6 | 7 | alectinib 600 mg BID | 7.6 | false | MSS | 2026-03-15T05:35:59.010404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417558 | REC_0008757 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 8.7 | 53 | male | 0 | 13 | 5.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 6.4 | false | MSS | 2026-03-15T05:35:59.010640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716858 | REC_0008758 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 6.4 | 68 | male | 0 | 47 | 3.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.2 | false | MSS | 2026-03-15T05:35:59.010876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945603 | REC_0008759 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 16.4 | 70 | female | 2 | 11 | 5.6 | 9 | osimertinib 80 mg daily | 4.7 | true | MSI-H | 2026-03-15T05:35:59.011112+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282753 | REC_0008760 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 7.2 | 70 | female | 2 | 0 | 4.2 | 1 | sotorasib 960 mg daily | 21.9 | false | MSS | 2026-03-15T05:35:59.011393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671763 | REC_0008761 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5 | 65 | female | 1 | 63 | 5.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.2 | false | MSS | 2026-03-15T05:35:59.011630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394576 | REC_0008762 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 7.9 | 85 | female | 2 | 51 | 3 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.5 | true | MSS | 2026-03-15T05:35:59.011857+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860322 | REC_0008763 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 16.4 | 70 | female | 1 | 12 | 6.2 | 7 | entrectinib 600 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:59.012178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_746552 | REC_0008764 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 9.2 | 62 | female | 0 | 10 | 6.2 | 5 | sotorasib 960 mg daily | 4.8 | true | MSS | 2026-03-15T05:35:59.012418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323477 | REC_0008765 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 15.8 | 75 | female | 1 | 16 | 4.5 | 1 | osimertinib 80 mg daily | 7.4 | true | MSS | 2026-03-15T05:35:59.012651+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634569 | REC_0008766 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 9.8 | 72 | female | 0 | 12 | 5.5 | 5 | osimertinib 80 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:59.012881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_479443 | REC_0008767 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 4.7 | 82 | male | 0 | 20 | 4.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.9 | true | MSS | 2026-03-15T05:35:59.013114+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458990 | REC_0008768 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 13.4 | 68 | female | 0 | 15 | 4.4 | 6 | osimertinib 80 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:59.013347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300290 | REC_0008769 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 8.5 | 59 | female | 0 | 22 | 5.7 | 1 | sotorasib 960 mg daily | 17.8 | false | MSS | 2026-03-15T05:35:59.013663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413807 | REC_0008770 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 12.5 | 60 | female | 1 | 4 | 6.3 | 4 | alectinib 600 mg BID | 9 | true | MSI-H | 2026-03-15T05:35:59.013901+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345707 | REC_0008771 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 6.9 | 67 | female | 0 | 12 | 7.5 | 5 | pembrolizumab 200 mg q3w | 14 | true | MSS | 2026-03-15T05:35:59.014135+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753891 | REC_0008772 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 16.7 | 70 | female | 2 | 16 | 5.3 | 6 | osimertinib 80 mg daily | 8 | false | MSI-H | 2026-03-15T05:35:59.014366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613942 | REC_0008773 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6 | 66 | female | 0 | 40 | 3.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.9 | true | MSS | 2026-03-15T05:35:59.014596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566740 | REC_0008774 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 6.4 | 66 | female | 1 | 15 | 4.2 | 5 | alectinib 600 mg BID | 10.1 | false | MSS | 2026-03-15T05:35:59.014822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514613 | REC_0008775 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 13.1 | 78 | female | 1 | 19 | 5.7 | 7 | osimertinib 80 mg daily | 7.8 | true | MSS | 2026-03-15T05:35:59.015058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493513 | REC_0008776 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.6 | 68 | female | 1 | 41 | 4.9 | 3 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:59.015340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_555157 | REC_0008777 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 13.3 | 67 | male | 0 | 15 | 6.1 | 4 | entrectinib 600 mg daily | 10.4 | true | MSI-H | 2026-03-15T05:35:59.015577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952516 | REC_0008778 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 14 | 11.3 | 76 | female | 2 | 18 | 6.2 | 4 | osimertinib 80 mg daily | 15.6 | true | MSS | 2026-03-15T05:35:59.015814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124792 | REC_0008779 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 9.9 | 54 | female | 0 | 3 | 7.4 | 4 | entrectinib 600 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:59.016044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961773 | REC_0008780 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 8.5 | 64 | male | 1 | 67 | 4.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 9 | false | MSS | 2026-03-15T05:35:59.016384+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617662 | REC_0008781 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 12.1 | 76 | female | 0 | 14 | 5.4 | 9 | osimertinib 80 mg daily | 18.9 | false | MSS | 2026-03-15T05:35:59.016620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915884 | REC_0008782 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 14.4 | 75 | female | 1 | 18 | 4.9 | 6 | osimertinib 80 mg daily | 4.5 | false | MSS | 2026-03-15T05:35:59.016856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148985 | REC_0008783 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 12.4 | 59 | male | 1 | 14 | 3.9 | 1 | entrectinib 600 mg daily | 13.8 | true | MSS | 2026-03-15T05:35:59.017095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312409 | REC_0008784 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 14 | 58 | female | 0 | 16 | 6.4 | 6 | osimertinib 80 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:35:59.017329+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_418542 | REC_0008785 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 10.4 | 66 | male | 0 | 8 | 5.7 | 5 | pembrolizumab 200 mg q3w | 15.3 | false | MSI-H | 2026-03-15T05:35:59.017563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963651 | REC_0008786 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 26 | 7.5 | 74 | female | 3 | 16 | 5.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 35.2 | true | MSS | 2026-03-15T05:35:59.017788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_206886 | REC_0008787 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 2.5 | 71 | male | 1 | 8 | 6.3 | 5 | alectinib 600 mg BID | 10 | false | MSS | 2026-03-15T05:35:59.018025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750224 | REC_0008788 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 15.4 | 57 | male | 1 | 10 | 6.4 | 1 | entrectinib 600 mg daily | 10 | true | MSS | 2026-03-15T05:35:59.018258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367003 | REC_0008789 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 16 | 60 | female | 1 | 5 | 4 | 3 | osimertinib 80 mg daily | 16.4 | true | MSS | 2026-03-15T05:35:59.018543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860978 | REC_0008790 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 10.7 | 58 | male | 0 | 18 | 4.3 | 2 | pembrolizumab 200 mg q3w | 19.9 | true | MSI-H | 2026-03-15T05:35:59.018781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356296 | REC_0008791 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 19.1 | 68 | female | 1 | 15 | 4.1 | 2 | osimertinib 80 mg daily | 9 | false | MSI-H | 2026-03-15T05:35:59.019013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254071 | REC_0008792 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 8.7 | 76 | female | 1 | 15 | 5.8 | 2 | osimertinib 80 mg daily | 8.9 | false | MSS | 2026-03-15T05:35:59.019244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366307 | REC_0008793 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 8.3 | 68 | female | 0 | 18 | 3.8 | 3 | osimertinib 80 mg daily | 14.8 | true | MSS | 2026-03-15T05:35:59.019472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200735 | REC_0008794 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 16.3 | 70 | female | 1 | 18 | 5.1 | 8 | pembrolizumab 200 mg q3w | 5.3 | true | MSI-H | 2026-03-15T05:35:59.019701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354042 | REC_0008795 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.1 | 55 | female | 0 | 36 | 8.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.9 | true | MSS | 2026-03-15T05:35:59.019932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822603 | REC_0008796 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 16.3 | 66 | female | 1 | 14 | 4.8 | 6 | entrectinib 600 mg daily | 8 | false | MSI-H | 2026-03-15T05:35:59.020231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837737 | REC_0008797 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 12.9 | 63 | female | 0 | 21 | 5.3 | 4 | pembrolizumab 200 mg q3w | 17.1 | false | MSI-H | 2026-03-15T05:35:59.020484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_195756 | REC_0008798 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 16 | 64 | female | 1 | 26 | 5.3 | 3 | entrectinib 600 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:59.020726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865634 | REC_0008799 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 18.1 | 74 | female | 2 | 11 | 4.2 | 1 | osimertinib 80 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:35:59.020960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275966 | REC_0008800 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 17.9 | 77 | female | 2 | 10 | 5.4 | 1 | entrectinib 600 mg daily | 28.9 | false | MSS | 2026-03-15T05:35:59.021195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.